Remicade Biosimilars: Samsung Looks To Follow Celltrion's Footsteps
This article was originally published in The Pink Sheet Daily
Executive Summary
351(k) application relies on data extrapolation from Phase III trial in rheumatoid arthritis to support approval across infliximab's indications, including inflammatory bowel disease.